Relating to authorizing the Department of Health to promulgate a legislative rule relating to the Safe Harbor Letter for the Medical Cannabis Program
Summary
HB2249 is a legislative rule authorization bill that approves a Department of Health rule concerning the Safe Harbor Letter for the Medical Cannabis Program. The bill does not create a new medical cannabis program or change the underlying medical cannabis statute directly; instead, it gives legislative approval to a previously filed administrative rule, identified as 64 CSR 113, governing how safe harbor letters are handled within the program.
In practical terms, the bill allows the Department of Health to move forward with implementing and enforcing the rule as part of the state’s medical cannabis regulatory framework. Safe harbor letters are generally used to provide patients or participants with documentation intended to reduce legal risk under certain circumstances, so the bill affects how the medical cannabis program is administered rather than expanding eligibility or changing patient rights in the statute itself.
Impact
The bill amends and reenacts West Virginia Code §64-5-1 to authorize a specific legislative rule from the Department of Health. Its legal effect is to validate the administrative rulemaking for the Safe Harbor Letter for the Medical Cannabis Program, thereby allowing the rule to take effect and be enforced. The bill primarily affects the Department of Health, medical cannabis patients, and any other parties subject to the program’s compliance and documentation requirements.
Sentiment
The available record shows no committee transcript, recorded vote, or other debate, so there is no documented public sentiment in the materials provided. Based on the bill’s narrow scope as a rule authorization measure, it appears to be a routine administrative bill rather than a controversial policy change.
Contention
No specific points of contention are identified in the provided materials. Because the bill simply authorizes a Department of Health rule, any disagreement would likely center on the details of the safe harbor letter process, the scope of administrative discretion, or how the rule affects medical cannabis participants and enforcement, but none of those concerns are documented here.